5 big analyst AI moves: Nvidia guidance warning; Snowflake, Palo Alto upgraded
Broadwood Partners, L.P., a significant stakeholder in Staar Surgical Co. (NASDAQ:STAA), has recently increased its position in the company by purchasing additional common stock. According to the latest SEC filing, the firm acquired shares worth a total of $481,849. The purchase prices for these transactions ranged from $16.30 to $17.74 per share, coming at a significant discount to the stock’s 52-week high of $52.68, as the shares have declined nearly 49% over the past year.
The transactions, carried out on March 4, 2025, saw Broadwood Partners increase its holdings in Staar Surgical to 11,981,151 shares. The purchases were made through Broadwood Capital, Inc., with Neal C. Bradsher, the President of Broadwood Capital, involved in the transactions. Notably, the reported securities are directly owned by Broadwood Partners and may be indirectly beneficially owned by Broadwood Capital and Neal C. Bradsher. The company maintains a strong balance sheet with a healthy current ratio of 5.23 and minimal debt-to-equity of 0.10.
These transactions highlight the continued interest and investment by Broadwood Partners in Staar Surgical, a company specializing in ophthalmic goods. While the company maintains strong financial health according to InvestingPro metrics, analysts have recently revised earnings expectations downward and anticipate a sales decline in the current year. For deeper insights into STAA’s valuation and growth prospects, investors can access comprehensive analysis through InvestingPro’s detailed research reports.
In other recent news, STAAR Surgical ’s Q4 2024 earnings report revealed a significant miss on both earnings per share (EPS) and revenue, with EPS at -$0.69 compared to the forecasted -$0.03, and revenue at $48.95 million against an expected $77.2 million. This earnings miss has raised concerns among investors and analysts, leading to several adjustments in stock ratings and price targets. Canaccord Genuity reduced its price target for STAAR Surgical to $17 while maintaining a Hold rating, citing the company’s low stock valuation compared to its peers. Jefferies also downgraded the stock, lowering its target from $60 to $18, reflecting uncertainties in STAAR Surgical’s revenue prospects, particularly in the Chinese market. Stifel, however, maintained a Buy rating despite cutting the price target to $20, attributing the adjustment to challenges in the Chinese market and increased inventory levels. Analysts from these firms have expressed varying degrees of cautious optimism, highlighting the need for market stabilization in China and improvements in global demand for refractive surgery. Despite the setbacks, STAAR Surgical maintains a strong cash position, ending FY2024 with $230.5 million, and plans to focus on its EVO ICL (TASE:ICL) technology and the upcoming launch of EVO Plus in China.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.